Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8358601 | 0.89 | ADRB1 (0.42) | ADRB1LMNAALOX5RAB9AGAA | |
| SCHEMBL17195399 | 0.81 | PTPN1 (0.50) | ADRB1ALOX5RAB9AGAACMA1 | |
| SCHEMBL10192172 | 0.80 | ADRB1 (0.50) | ADRB1ALOX5GAAKMT2AMEN1 | |
| SCHEMBL17233009 | 0.78 | ADRB2 (0.44) | PIK3C3 | |
| SCHEMBL15419810 | 0.71 | CRY1 (0.40) | LMNARAB9APIK3C3NPC1SMN1; SMN2 | |
| SCHEMBL15420000 | 0.70 | PTPN1 (0.47) | ADRB1ALOX5RAB9APIK3C3KMT2A | |
| SCHEMBL17233331 | 0.70 | PIK3C3 (0.36) | PIK3C3 | |
| SCHEMBL8358602 | 0.69 | PIK3C3 (0.42) | RAB9AELANEPIK3C3NPC1SMN1; SMN2 | |
| SCHEMBL16037169 | 0.69 | PTPN1 (0.46) | ADRB1ALOX5RAB9AKMT2AMEN1 | |
| SCHEMBL1688165 | 0.69 | PTPN1 (0.69) | LMNAALOX5RAB9AGAACMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | ADRB1 2630/4885LMNA 4373/4885ALOX5 883/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | ADRB1 1683/4885LMNA 1241/4885ALOX5 855/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | ADRB1 2943/4885LMNA 3101/4885ALOX5 575/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ADRB1 4150/4885LMNA 1012/4885ALOX5 2791/4885 |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | SMO, SHH, SOS1 | ADRB1 4706/4885LMNA 4738/4885ALOX5 4258/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ADRB1 4150/4885LMNA 1012/4885ALOX5 2791/4885 |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | SMO, SHH, SOS1 | ADRB1 4706/4885LMNA 4738/4885ALOX5 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.